Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676305 | 0.83 | ALDH1A1 (0.46) | ALDH1A1GAAKDM1AMAPTTHRB | |
| SCHEMBL4886895 | 0.83 | MCHR1 (0.39) | ALDH1A1MAPTTHRBMEN1KMT2A | |
| SCHEMBL28026234 | 0.82 | ALDH1A1 (0.39) | ALDH1A1GAAKDM1AMAPTTHRB | |
| SCHEMBL596640 | 0.79 | L3MBTL1 (0.37) | ALDH1A1GAALMNAMAPTMEN1 | |
| SCHEMBL8490254 | 0.79 | ALDH1A1 (0.42) | ALDH1A1GAALMNAMAPTMEN1 | |
| SCHEMBL4885840 | 0.78 | HPGD (0.38) | ALDH1A1GAAMAPTMEN1KMT2A | |
| SCHEMBL4885849 | 0.76 | CSNK2A1 (0.44) | ALDH1A1GAATP53MAPTMEN1 | |
| SCHEMBL4890755 | 0.76 | L3MBTL1 (0.33) | ALDH1A1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL446382 | 0.76 | CSNK2A1 (0.40) | LMNAMEN1KMT2A | |
| SCHEMBL4888707 | 0.75 | SSTR4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | claimed |
| EP-2750677-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| WO-2013033085-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | claimed |
| EP-3243515-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-9981918-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3243515-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2750677-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | disclosed |
| EP-2750677-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033085-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | disclosed |
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | CULSHAW ANDREW JAMES | 2008-11-27 | — | — | US | disclosed |
| CN-100432059-C | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2008-11-12 | — | — | CN | disclosed |
| CN-1711249-A | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | OPRK1, OPRL1, TRPV1 | ALDH1A1 650/4885GAA 2753/4885KDM1A 2660/4885 |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | ALDH1A1 1261/4885GAA 264/4885KDM1A 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.